Exit interview: FDA legend Janet Woodcock’s thoughts on the agency and its controversies

For al­most four decades, Janet Wood­cock has served in near­ly every ma­jor lead­er­ship po­si­tion at the FDA — act­ing com­mis­sion­er, deputy com­mis­sion­er, CDER di­rec­tor, Of­fice of New Drugs di­rec­tor, COO and more.

Wood­cock of­fi­cial­ly re­tires on Wednes­day and sat down with End­points News via video con­fer­ence to talk about how she would re­form the ad­vi­so­ry com­mit­tee sys­tem, why we’re not ready for the next pan­dem­ic, and what she would’ve done dif­fer­ent­ly with Sarep­ta’s ac­cel­er­at­ed ap­proval for Ex­ondys 51 (eteplirsen) in 2016.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.